- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07840521
Investigating Near-Threshold Perception During Ultrasonic Deep Brain Stimulation
This research is studying changes in awareness and metabolism in the brain that may take place in various brain regions stimulated with ultrasound (low-intensity focused ultrasound pulsation or LIFUP) while undergoing magnetic resonance imaging (MRI)-based brain measurements.
Visão geral do estudo
Status
Condições
Descrição detalhada
This study examines the effects of low-intensity focused ultrasound pulsation (LIFUP) on conscious perception and brain physiology in healthy adults using functional Magnetic resonance imaging (MRI), magnetic resonance spectroscopy, or multimodal glymphatic MRI. Participants are assigned by the study team to one of three arms, each involving up to five visits targeting different prespecified brain regions. Participants perform a visual perception task during imaging, with measurements obtained before, during, and after LIFUP. After completing their initially assigned arm, participants may re-enroll in another arm or for a repeat visit following re-screening and new informed consent.
Randomization applies to the order of procedures within each arm, not to assignment of participants among the three arms. The order in which the five brain regions are targeted will be randomized across participants in all three experimental arms
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Amy McKinney
- Número de telefone: 734-647-8129
- E-mail: adrongo@med.umich.edu
Locais de estudo
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan
-
Contato:
- Amy McKinney
- Número de telefone: 734-647-8129
- E-mail: adrongo@med.umich.edu
-
Investigador principal:
- Zirui Huang
-
Investigador principal:
- Anthony Hudetz
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Participants must be right-handed, English-speaking, and capable of providing written informed consent.
- Participants must have normal or corrected-to-normal vision while wearing contact lenses,
- Participants must have a body mass index of less than 30
- Participants must not be taking medications for any neurological, psychological, or psychiatric condition.
Exclusion Criteria:
- Participants will be excluded if they have any contraindication to MRI scanning, including possible pregnancy, current breastfeeding BMI greater than 30, metallic substances or implants in the body, claustrophobia, anxiety that would prevent MRI scanning, Participants with tattoos in the head or neck region will also be excluded, while tattoos in other locations will be evaluated by the investigators to determine whether they pose a safety concern.
- cardiopulmonary disease, or an intracranial structural abnormality identified on T1-weighted MRI.
- Women of childbearing potential will be required to complete a study-funded pregnancy test before participation and must have a negative result.
- vision that is not 20/20 or corrected to 20/20 with contact lenses, a history of significant head injury involving loss of consciousness
- a learning disability or other developmental disorder
- any sensory or motor impairment, activity, condition, or circumstance that, in the judgment of the study coordinator or Principal Investigators, would prevent satisfactory completion of the study protocol.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: LIFUP-fMRI
Participants assigned to the fMRI arm will complete five visits, with a different brain region targeted at each visit. Each visit will include seven consecutive 10-minute scanning periods: one pre-LIFUP baseline fMRI scan, five fMRI scans conducted during LIFUP using five predefined combinations of duty cycle and pulse repetition frequency, and one post-LIFUP baseline fMRI scan. The five stimulation parameter combinations will be labeled Combination 1 through Combination 5. The order of the five parameter combinations will be randomized within each visit. The total planned scanning time for these seven periods is approximately 70 minutes, excluding structural imaging, participant positioning, transducer placement, safety checks, and other required study procedures. |
LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents. Whole-brain functional images will be acquired using a multiband gradient-echo echo-planar imaging sequence with the following parameters: 60 slices, repetition time (TR) = 800 ms, echo time (TE) = 30 ms, flip angle = 52°, multiband acceleration factor = 6, slice thickness = 2.4 mm, in-plane resolution = 2.4 × 2.4 mm, FOV = 216 × 216 mm, and image matrix = 90 × 90. MRI acquisition and associated study procedures will be completed within a scanning visit lasting no more than approximately 2 hours. |
|
Experimental: LIFUP-magnetic resonance spectroscopy (MRS)
Participants assigned to the MRS arm will also complete five visits, with a different brain region targeted at each visit. Each visit will include a pre-LIFUP baseline MRS acquisition, an excitatory LIFUP condition, a post-excitatory non-LIFUP MRS acquisition, an inhibitory LIFUP condition, and a post-inhibitory non-LIFUP MRS acquisition. Each MRS acquisition period will last approximately 13 minutes and will include approximately 5 minutes of glutamate plus glutamine measurement and 8 minutes of gamma-aminobutyric acid (GABA) measurement. The order of the excitatory and inhibitory LIFUP conditions will be randomized across participants. |
LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents. Single-voxel proton magnetic resonance spectroscopy will be performed. A nominal 15 × 15 × 10 mm spectroscopy voxel will be positioned at the prespecified brain target using the participant's anatomical MRI. Glutamate plus glutamine (Glx) will be measured using a short-echo-time spectroscopy sequence with an acquisition time of approximately 5 minutes. GABA will be measured using an edited spectroscopy sequence with an acquisition time of approximately 8 minutes. An unsuppressed water-reference scan will also be acquired for signal correction and metabolite quantification. Voxel placement, shimming, and other sequence parameters may be adjusted slightly based on target anatomy, scanner requirements, and data quality while maintaining the planned procedures and approximate acquisition times. |
|
Experimental: LIFUP-Glymphatic MRI
Participants assigned to the glymphatic MRI arm will complete up to five visits, with a different prespecified brain region targeted at each visit. Tissue-to-fluid water exchange, velocity spectrum imaging, and cerebral perfusion using arterial spin labeling will be assessed before, during, and after LIFUP. The planned imaging periods total approximately 1.5 hours per visit, excluding participant positioning, structural imaging, transducer placement, safety checks, and other required study procedures. |
LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents. The study team will collect three separate measurements related to glymphatic function. (i) Multi-delay pseudo-continuous arterial spin labeling (PCASL) MRI with a 3D stack of spirals (SOS) gradient and spin echo (GRASE) read-out. Labeling durations from 500 to 2000 ms, TR = 6 sec., background suppression. FOV = 24 cm with 3x3x5 mm resolution. (ii) Tissue-to-fluid Water exchange rate using T2 selective saturation labeling pulses using the same resolution parameters. (iii) Velocity Spectrum Imaging using velocity selective preparation pulses followed by spherical spiral projection imaging (FOV = 24 cm, velocity bandwidth = [-1, 1] cm/s, isotropic spatial resolution = 3.5 mm). |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Blood Oxygen Level Dependent (BOLD) response to visual stimuli
Prazo: Approximately 70 minutes
|
Changes in task-evoked blood oxygen level-dependent responses to visual stimuli will be measured using functional MRI before, during, and after LIFUP across the five stimulation parameter conditions. |
Approximately 70 minutes
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Perceptual criterion (c) derived from the Signal Detection Theory (SDT)
Prazo: Approximately 65-75 minutes
|
The perceptual response criterion, c, will be calculated from participants' recognition responses using Signal Detection Theory to quantify their tendency to report conscious recognition of a visual stimulus. For each scanning session, the study team will calculate sensitivity (d') and criterion (c) using subjective reports of recognition as "yes" or "no". |
Approximately 65-75 minutes
|
|
Perceptual sensitivity (d') derived from the Signal Detection Theory (SDT)
Prazo: Approximately 75 minutes
|
Perceptual sensitivity, d', will be calculated from participants' visual discrimination responses using Signal Detection Theory to quantify their ability to distinguish intact object images from control stimuli. For each scanning session, the study team will calculate sensitivity (d') and criterion (c) using subjective reports of recognition as "yes" or "no". |
Approximately 75 minutes
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Zirui Huang, University of Michigan
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Manifestações Neurocomportamentais
- Distúrbios Neurocognitivos
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Distúrbios da Consciência
- Técnicas de investigação
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Tomografia
- Diagnóstico imagens
- Técnicas de química, analíticas
- Análise de espectro
- Ressonância magnética
- Espectroscopia de ressonância magnética
Outros números de identificação do estudo
- HUM00251769
- 2R01GM103894 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .